Intellia Therapeutics (NTLA) Assets (2015 - 2026)
Intellia Therapeutics (NTLA) posted quarterly Assets of $758.8 million for Q1 2026, down 23.06% year-over-year from $986.2 million in Q1 2025, and down 9.9% quarter-over-quarter from $842.1 million in Q4 2025.
Intellia Therapeutics (NTLA) Assets (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Assets for 12 consecutive years, with $758.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets fell 23.06% year-over-year to $758.8 million; the TTM figure through Mar 2026 stood at $758.8 million (down 23.06% YoY), while the FY2025 annual figure was $842.1 million, down 29.29% from the prior year.
- Assets declined to $758.8 million in Q1 2026 per NTLA's latest filing, from $842.1 million in the prior quarter.
- Across five years, Assets topped out at $1.5 billion in Q4 2022 and bottomed at $758.8 million in Q1 2026.
- Historically, Assets has averaged $1.1 billion across 5 years, with a median of $1.2 billion in 2024.
- Annual changes were most pronounced in 2022 — Assets jumped 67.78% — and 2025, when it declined 29.29%.
- Intellia Therapeutics' Assets stood at $1.5 billion in 2022, then dropped by 14.42% to $1.3 billion in 2023, then declined by 8.45% to $1.2 billion in 2024, then slipped by 29.29% to $842.1 million in 2025, then decreased by 9.9% to $758.8 million in 2026.
- Business Quant data shows NTLA's Assets at $758.8 million in Q1 2026, $842.1 million in Q4 2025, and $925.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - | 857.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 857.16 Mn |
| Mar 31, 2026 | 758.78 Mn |
| Dec 31, 2025 | 842.13 Mn |
| Sep 30, 2025 | 925.28 Mn |
| Jun 30, 2025 | 898.89 Mn |
| Mar 31, 2025 | 986.16 Mn |
| Dec 31, 2024 | 1.19 Bn |
| Sep 30, 2024 | 1.17 Bn |
| Jun 30, 2024 | 1.19 Bn |
| Mar 31, 2024 | 1.26 Bn |
| Dec 31, 2023 | 1.30 Bn |
| Sep 30, 2023 | 1.24 Bn |
| Jun 30, 2023 | 1.32 Bn |
| Mar 31, 2023 | 1.42 Bn |
| Dec 31, 2022 | 1.52 Bn |
| Sep 30, 2022 | 1.08 Bn |
| Jun 30, 2022 | 1.11 Bn |
| Mar 31, 2022 | 1.20 Bn |
| Dec 31, 2021 | 1.29 Bn |
| Sep 30, 2021 | 1.33 Bn |